ES2645262T3 - Métodos de uso de CD24 soluble para terapia de artritis reumatoide - Google Patents

Métodos de uso de CD24 soluble para terapia de artritis reumatoide Download PDF

Info

Publication number
ES2645262T3
ES2645262T3 ES11778000.7T ES11778000T ES2645262T3 ES 2645262 T3 ES2645262 T3 ES 2645262T3 ES 11778000 T ES11778000 T ES 11778000T ES 2645262 T3 ES2645262 T3 ES 2645262T3
Authority
ES
Spain
Prior art keywords
soluble
methods
rheumatoid arthritis
protein
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11778000.7T
Other languages
English (en)
Spanish (es)
Inventor
Xincheng Zheng
Wei Wu
Yang Liu
Pan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Application granted granted Critical
Publication of ES2645262T3 publication Critical patent/ES2645262T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES11778000.7T 2010-04-28 2011-04-28 Métodos de uso de CD24 soluble para terapia de artritis reumatoide Active ES2645262T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
US329078P 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ES2645262T3 true ES2645262T3 (es) 2017-12-04

Family

ID=44903987

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11778000.7T Active ES2645262T3 (es) 2010-04-28 2011-04-28 Métodos de uso de CD24 soluble para terapia de artritis reumatoide
ES17183045T Active ES2826445T3 (es) 2010-04-28 2011-04-28 Uso médico de CD24 soluble

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17183045T Active ES2826445T3 (es) 2010-04-28 2011-04-28 Uso médico de CD24 soluble

Country Status (17)

Country Link
US (1) US8808697B2 (enExample)
EP (3) EP3260128B1 (enExample)
JP (5) JP5899206B2 (enExample)
KR (1) KR20130086126A (enExample)
CN (2) CN102869369B (enExample)
AU (1) AU2011248540B2 (enExample)
CA (1) CA2795823C (enExample)
DK (1) DK2563385T3 (enExample)
EA (2) EA036805B8 (enExample)
ES (2) ES2645262T3 (enExample)
IL (1) IL222739A0 (enExample)
NO (1) NO2563385T3 (enExample)
NZ (1) NZ603196A (enExample)
PL (2) PL2563385T3 (enExample)
PT (2) PT3260128T (enExample)
SG (1) SG184907A1 (enExample)
WO (1) WO2011139820A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EA038520B1 (ru) * 2015-05-07 2021-09-09 Онкоиммьюн, Инк. Применение гуманизированного слитого белка cd24 для снижения уровней холестерина липопротеинов низкой плотности
US10799558B2 (en) * 2016-02-02 2020-10-13 Oncoimmune, Inc. Use of CD24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
CN110650749A (zh) * 2017-05-15 2020-01-03 肿瘤免疫股份有限公司 使用可溶性cd24进行神经保护和髓鞘再生的方法
EP3630158B1 (en) * 2017-05-22 2022-07-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
WO2019222082A1 (en) * 2018-05-14 2019-11-21 Oncoimmune, Inc. Anti-cd24 compositions and uses thereof
BR112020024659A2 (pt) * 2018-06-04 2021-03-09 Oncoimmune, Inc. Métodos de uso de cd24 para a prevenção e tratamento de recaída de leucemia
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
EP4251130A4 (en) * 2020-11-30 2024-12-11 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
WO2023051480A1 (en) * 2021-09-28 2023-04-06 Acroimmune Guangzhou Biotech Ltd Fusion proteins comprising 071 core peptide and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
BR0207267A (pt) * 2001-02-19 2004-02-10 Merck Patent Gmbh Proteìnas artificiais com imunogenicidade reduzida
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
PL367329A1 (en) * 2001-07-13 2005-02-21 Merck Patent Gmbh Methods for reducing immunogenicity of polypeptides
DK1569685T3 (da) * 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
CA2549913A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
NO2563385T3 (enExample) 2017-12-30
WO2011139820A8 (en) 2013-02-07
JP2015187162A (ja) 2015-10-29
JP2019151655A (ja) 2019-09-12
CN105381451B (zh) 2021-03-09
EP3260128B1 (en) 2020-07-29
HK1176007A1 (zh) 2013-07-19
EP2563385B1 (en) 2017-08-02
CA2795823A1 (en) 2011-11-10
EA036805B8 (ru) 2021-02-25
PT2563385T (pt) 2017-11-10
IL222739A0 (en) 2012-12-31
JP6888221B2 (ja) 2021-06-16
JP2013527168A (ja) 2013-06-27
JP6526872B2 (ja) 2019-06-05
PT3260128T (pt) 2020-10-22
EP2563385A4 (en) 2013-10-02
AU2011248540B2 (en) 2014-11-20
DK2563385T3 (da) 2017-11-06
NZ603196A (en) 2014-07-25
JP2018127493A (ja) 2018-08-16
SG184907A1 (en) 2012-11-29
EP2563385A1 (en) 2013-03-06
EA201290961A1 (ru) 2013-04-30
PL3260128T3 (pl) 2021-02-08
HK1222554A1 (zh) 2017-07-07
WO2011139820A1 (en) 2011-11-10
JP2017057216A (ja) 2017-03-23
ES2826445T3 (es) 2021-05-18
CN102869369B (zh) 2016-05-18
EA201790538A3 (ru) 2017-11-30
EA036805B1 (ru) 2020-12-23
CN102869369A (zh) 2013-01-09
JP6062502B2 (ja) 2017-01-18
KR20130086126A (ko) 2013-07-31
US8808697B2 (en) 2014-08-19
EA027735B1 (ru) 2017-08-31
JP5899206B2 (ja) 2016-04-06
PL2563385T3 (pl) 2018-04-30
US20130136739A1 (en) 2013-05-30
EA201790538A2 (ru) 2017-07-31
CA2795823C (en) 2019-06-04
EP3260128A1 (en) 2017-12-27
CN105381451A (zh) 2016-03-09
EP3845238A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
ES2645262T3 (es) Métodos de uso de CD24 soluble para terapia de artritis reumatoide
JP7238000B2 (ja) 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
ES2626268T3 (es) Método de purificación de proteínas
ES2594408T3 (es) Método para purificar albúmina sérica humana a partir de grano de arroz transgénico
ES2769783T3 (es) Procedimiento de purificación de inmunoglobulina
ES2924109T3 (es) Composición que comprende una mezcla de isoformas de CD95-Fc
AU2011229491B2 (en) Method for obtaining biologically active recombinant human G-CSF
CN113382716A (zh) 通过将药物物质和药物产品过程整体化的生物制剂制造的连续制造过程
FI4108259T3 (fi) Prosessi vasta-aineiden konsentroimiseksi ja niiden terapeuttisia tuotteita
ES2569343T3 (es) Procedimiento para extraer albúmina sérica humana a partir de grano de arroz transgénico
ES2224094T3 (es) Procedimiento para preparar seroalbumina normal (humana) esencialmente monomerica.
ES2294696T3 (es) Metodo de purificacion de albumina que incluye una etapa de nanofiltracion, solucion y composicion para uso terapeutico que la contiene.
ES2031438T5 (es) Metodo para la purificacion de proteinas.
CN102199198A (zh) 人呼吸道合胞病毒f蛋白的纯化方法
CN112375142B (zh) 静注新型冠状病毒人免疫球蛋白的制备方法
CN103111270B (zh) 一种乙型肝炎抗原蛋白的吸附材料及其制备方法
CN114195858B (zh) 多肽及其改造体和在制备抗炎杀菌药物中的应用
US20190002537A1 (en) Method for enriching a preparation of immunoglobulins with anti rsv immunoglobulins and preparation enriched in this way
ES2717683T3 (es) Métodos de preparación para una generación novedosa de productos de KLH biológicamente seguros usados para el tratamiento contra el cáncer, para el desarrollo de vacunas terapéuticas conjugadas y como agentes de exposición
ES2717709T3 (es) Métodos de preparación para una generación novedosa de productos de KLH biológicamente seguros usados para el tratamiento de cáncer, para el desarrollo de vacunas terapéuticas conjugadas y como agentes de exposición
AU5955294A (en) Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
CN104109199B (zh) 一种聚乙二醇单修饰的人粒细胞集落刺激因子的制备方法及其产品
JPS6030292B2 (ja) 人顆粒球の分化増殖を促進する加熱処理ｈｇｉｇｐ及びｈｇｉｇｐの加熱処理法
WO2022101666A1 (en) Modular manufacturing unit, and components and methods for manufacturing infectious disease therapeutics using same
NO300895B1 (no) Fremgangsmåte for rensing av et humant rå-leukocyttinterferon